Default company panoramic image

TVAX Biomedical, Inc.

TVAX Immunotherapy is a new approach to the treatment of cancer offering the promise of improved clinical outcomes and reduced side effects.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lenexa, KS, USA
  • Currency USD
  • Founded November 2004
  • Employees 7
  • Website

Company Summary

TVAX Biomedical is advancing a Phase 3-ready brain cancer program. The company's unique therapy combines personalized cancer cell vaccination and “killer” T cell treatment without the undesirable side effects associated with radiation and chemotherapy. The TVAX advantage within the cancer immunotherapy space is that TVAX is the first and currently only company in the world to combine these two approaches into one potent treatment platform.


  • Default avatar
    Phil Haworth, Ph.D., JD
    Chief Executive Officer

    TVAX’s Chief Executive Officer, possesses almost 30 years of management experience in the biotechnology industry. He most recently served as the chief executive officer of Intradigm Corporation and then Silence Therapeutics following that company’s merger with Intradigm. In these positions, Dr. Haworth spearheaded all clinical, operational and fundraising efforts, helping position Intradigm/Silence as a leader in the emerging area of RNA interfe

  • Default avatar
    Gary W. Wood, Ph.D.
    Chief Science Officer

    Gary W. Wood, Ph.D. founded TVAX Biomedical in 2004 and has served as our President, Chief Executive Officer and Chairman of the Board of Directors since inception. Dr. Wood is the inventor and principal developer of the TVAX Immunotherapy technology. Dr. Wood guided the development of TVAX Immunotherapy from concept through its most recent human clinical trials. Dr. Wood organized and coordinated the Phase I/II clinical trials performed at Unive

  • Default avatar
    Tammie A. Wahaus
    Chief Financial Officer

    Tammie A. Wahaus, CPA, CGMA joined TVAX Biomedical in 2012 and serves as our Chief Financial Officer and prior to that provided services as a consultant to the company. Ms. Wahaus has more than 25 years of experience in both public accounting and private business. She has served as Vice President-Finance for Epiq Systems, Inc., as an audit partner with Ernst & Young LLP providing services to public and private companies and as Controller and Pri

  • Default avatar
    Beth Lucasey
    VP Communications and Marketing

    Beth Lucasey, M.A., BSN is a cofounder and has served as a director since inception. Ms. Lucasey has been our Vice President for Communications and Marketing since 2010. From 1990 through 2011, Ms. Lucasey worked as the nurse manager of the Endocrine Division at the University of Kansas Medical Center. Ms. Lucasey is a registered nurse with 25 years of experience in the health care industry with research, consumer education and direct patient car


  • Default avatar
    Stinson, Morrison, Hecker
    Default avatar
    Ernst & Young